Contrasting roles of the ABCG2 Q141K variant in prostate cancer

Kathryn M Sobek1, Jessica L Cummings2, Dean J Bacich3

  • 1Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Insights

The ABCG2 Q141K variant impacts prostate cancer recurrence and survival. This variant reduces folate efflux, accelerating recurrence, but also decreases docetaxel efflux, improving survival in treated patients, suggesting genotype-guided treatment.

Area of Science:

  • Oncology
  • Pharmacogenomics
  • Molecular Biology

Background:

  • ABCG2 is a membrane transporter affecting drug and molecule efflux.
  • The ABCG2 Q141K variant is linked to prostate cancer outcomes.
  • Understanding ABCG2 variant function is crucial for personalized treatment.

Purpose of the Study:

  • To investigate the functional impact of the ABCG2 Q141K variant on prostate cancer.
  • To correlate ABCG2 genotype with time to PSA recurrence and survival.
  • To elucidate the mechanisms behind the variant's contrasting effects on tumor growth and drug response.

Main Methods:

  • Analysis of PSA recurrence in prostate cancer patients with different ABCG2 genotypes.
  • In vitro transport assays measuring folic acid and docetaxel efflux.
  • Confocal microscopy of ABCG2 expression in human prostate cancer tissues.

Main Results:

  • The ABCG2 Q141K variant was associated with a shorter time to PSA recurrence.
  • Q141K variant showed reduced folic acid efflux compared to wild-type.
  • Q141K variant exhibited less efficient docetaxel efflux, potentially increasing drug sensitivity.

Conclusions:

  • The ABCG2 Q141K variant has dual roles in prostate cancer, influencing recurrence and treatment response.
  • Decreased folate efflux by Q141K enhances proliferation and shortens recurrence time.
  • Reduced docetaxel efflux by Q141K may improve survival in treated patients.
  • ABCG2 genotype may guide personalized prostate cancer treatment strategies.

Related Concept Videos

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
81
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56